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Summary
Background Interest is growing in digital and telehealth delivery of mental health services, but data are scarce on 
outcomes in routine care. The federally funded Australian MindSpot Clinic provides online and telephone psychological 
assessment and treatment services to Australian adults. We aimed to summarise demographic characteristics and 
treatment outcomes of patients registered with MindSpot over the first 7 years of clinic operation.
Methods We used an observational design to review all patients who registered for assessment with the MindSpot 
Clinic between Jan 1, 2013, and Dec 31, 2019. We descriptively analysed the demographics, service preferences, and 
baseline symptoms of patients. Among patients enrolled in a digital treatment course, we evaluated scales of depression 
(Patient Health Questionnaire-9 [PHQ-9]) and anxiety (Generalized Anxiety Disorder 7-Item Scale [GAD-7]), as primary 
measures of treatment outcome, from the screening assessment to post-treatment and a 3 month follow-up. The 
Kessler Psychological Distress 10-Item Plus Scale was also used to assess changes in general distress and disability, 
and course satisfaction was measured post-treatment.
Outcomes A total of 121 652 screening assessments were started, of which 96 018 (78·9%) were completed. The 
mean age of patients was 35·7 years (SD 13·8) and 88 702 (72·9%) were women. Based on available assessment 
data, 36 866 (34·5%) of 106 811 participants had never previously spoken to a health professional about their 
symptoms, and most people self-reported symptoms of anxiety (88 879 [81·9%] of 108 494) or depression (78 803 
[72·6%] of 108 494), either alone or in combination, at baseline. 21 745 patients started treatment in a therapist-guided 
online course, of whom 14 503 (66·7%) completed treatment (≥four of five lessons). Key trends in service use 
included an increase in the proportion of people using MindSpot primarily for assessment and information, from 
52·6% in 2013 to 66·7% in 2019, while the prop ortion primarily seeking online treatment decreased, from 42·6% 
in 2013 to 26·7% in 2019. Effect sizes and percentage changes were large for estimated mean scores on the PHQ-9 
and GAD-7 from assessment to post-treatment (PHQ-9, Cohen’s d effect size 1·40 [95% CI 1·37–1·43]; and GAD-7, 
1·45 [1·42–1·47]) and the 3 month follow-up (PHQ-9, 1·36 [1·34–1·38]; and GAD-7, 1·42 [1·40–1·44]); proportions 
of patients with reliable symptom deterioration (score increase of ≥6 points [PHQ-9] or ≥5 points [GAD-7]) were low 
post-treatment (of 13 058 respondents, 184 [1·4%] had symptom deterioration on the PHQ-9 and 282 [2·2%] on the 
GAD-7); and patient satisfaction rates were high (12 452 [96·6%] of 12 895 respondents would recommend the 
course and 12 433 [96·7%] of 12 860 reported the course worthwhile). We also observed small improvements in 
disability following treatment as measured by days out of role.
Interpretation Our findings indicate improvement in psychological symptoms and positive reception among 
patients receiving online mental health treatment. These results support the addition of digital services such as 
MindSpot as a component in contemporary national mental health systems.
Funding None.
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Introduction
Mental disorders and substance use disorders are 
major contributors to the burden of disease in Australia1 
and worldwide,2,3 with only a minority of those affected 
see king or receiving evidence-based treatments.4,5 
Barriers to care include stigma, cost, and availability of 
services.6 The COVID-19 pandemic has created 
additional challenges, as many traditional mental 
health providers stopped pro viding face-to-face service. 
As a result, interest is increasing in the digital delivery 
of psycho logical services.7 Digital mental health services 
(DMHS) remotely deliver mental health information, 
assessments, and treatment, via the internet, telephone, 
or other digital channels. DMHS are already part of 
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routine care in several coun tries, operating either as 
stand-alone services or in con junction with traditional 
face-to-face care.8,9 For example, the Improving Access 
to Psychological Therapies (IAPT) service of the 
National Health Service (England) provides both face-
to-face and digital services to patients with anxiety or 
dep ression; a stepped-care approach that allows 
patients to move from low-intensity intervention (such 
as guided self-help) to high-intensity intervention 
(tradi tional face-to-face therapy).9 Stepped care is not a 
common feature of stand-alone DMHS, in which 
patients often report being un willing or unable to 
access traditional face-to-face therapy.10
In this paper, we report outcomes from the Australian 
MindSpot Clinic, which by volume of patients, is one of 
the world’s largest publicly funded DMHS. The 
MindSpot project was launched in December, 2012, and 
is funded by the Australian Department of Health as 
part of the Australian Government’s e-Mental Health 
Strategy.11 MindSpot provides information about 
symptoms and local mental health services, brief psycho-
logical assess ments, and therapist-guided treatments 
delivered via the internet and telephone to adults with 
symp toms of anxiety, dep ression, or chronic pain. We 
have previously reported results from 12 months12 and 
30 months10 of operations, characteristics of service 
users during the COVID-19 pan demic,13 and treatment 
outcomes for specific populations, including Aboriginal 
and Torres Strait Islander (Indig enous) people14 and 
people born overseas.15 In this paper, we aimed to 
provide a summary of demographic charac teristics and 
treat ment outcomes for patients registered with 
MindSpot over its first 7 years of operation, including 
service use and symptom severity, and examined trends 
in these characteristics over time.
Methods
Design and participants
This study was designed as an observational study and is 
reported according to STROBE guidelines.16 We evaluated 
all patients who registered for assessment or treatment 
with the MindSpot Clinic between Jan 1, 2013, and Dec 31, 
2019. Ethical approval for the collection and use of patient 
data was obtained from the Macquarie University Human 
Research Ethics Committee (Macquarie University, 
Sydney, NSW, Australia; approval number 5201200912) 
and registered on the Australian and New Zealand Clinical 
Trials Registry, ACTRN12613000407796. MindSpot is 
funded by the Australian Government as a project and 
recruitment is ongoing as patients continue to access the 
service.
As MindSpot is funded by the Australian Department 
of Health, patients seeking assessment or treatment 
must complete an online registration questionnaire and 
meet the following eligibility criteria: Australian 
resident eligible for publicly funded health services (ie, 
Medicare-funded services); aged 18 years or older; and 
self-reported principal complaint of anxiety, depression, 
or chronic pain. Patients are also provided with the 
terms of use explaining that non-identifiable, aggregated 
data could be used for reporting and service evaluation 
purposes. Patients are required to consent to the terms 
For Australian MindSpot Clinic 
see www.mindspot.org.au
Research in context
Evidence before this study
Digital mental health services (DMHS) remotely deliver mental 
health information, assessments, and treatment services, 
via the internet, telephone, or other digital channels. We 
searched PubMed on Jun 12, 2020 (repeated Sept 30, 2020), 
with the terms (English [Language]) AND ((Internet [Title/
Abstract]) AND (mental health services [Title/Abstract])), 
without date restrictions. We identified more than 
250 published reports of internet-delivered structured 
psychological treatments mostly for anxiety, depression, and 
somatic disorders. With some exceptions, most trials have 
shown large and clinically significant reductions in target 
symptoms. DMHS are now delivered as part of routine care in 
several countries, including Australia, Canada, Denmark, the 
Netherlands, Norway, and Sweden. Successful implementation 
is associated with high standards of clinical and organisational 
governance, and robust systems for training and supervision of 
therapists. Health-care providers in other countries have now 
either developed or are exploring strategies for introducing 
DMHS into health-care frameworks. However, information is 
scarce on usability, real world effectiveness, patient 
demographics, and the reasons patients choose to use DMHS.
Added value of this study
This study describes the characteristics and treatment outcomes 
of a large sample of consecutive users (n=121 652) of the 
national Australian DMHS, MindSpot Clinic, from data collected 
over its first 7 years of operations. We provide information about 
the demographic characteristics, service preferences, symptoms, 
and treatment outcomes for people using this particular model 
of digital service. We found that clinic users represented a broad 
cross-section of the Australian population, and used MindSpot 
for a variety of reasons, with most seeking a confidential 
assessment rather than treatment. We also found that people 
who engaged in treatment achieved significant reductions in 
symptoms, which were sustained 3 months after treatment 
completion. Importantly, these findings confirm the role of 
DMHS in providing evidence-based assessment and treatment 
to large numbers of people, many of whom are not accessing 
other services.
Implications of all the available evidence
The present findings contribute to the evidence base for DMHS 
in reducing barriers to care, and confirm the utility of DMHS as an 
important component of contemporary mental health systems.
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of use, either online or by telephone, before proceeding 
with assessment and treatment.
Clinical model
The MindSpot clinical model was developed in colla-
boration with patients, referrers, res earchers, and the 
requirements of the Australian Department of Health. 
Clinic services are pro vided at no cost to patients. The 
MindSpot website provides information about symptoms 
and management of anxiety, depression, and chronic 
pain, as well as information about MindSpot. It includes 
online versions of several symptom screening question-
naires that can be used anonymously by all visitors to the 
website (ie, without registering for a MindSpot service), 
and which generate advice about self-management. 
Information on the website is available to the general 
public in Australia and overseas, and is viewed by more 
than 500 000 unique visitors each year. People can also 
telephone and email the MindSpot Clinic for information 
about symptoms and advice about services. Users report 
learning about MindSpot via social media, website 
searches, family and friends, and referrals from other 
health services. MindSpot is promoted via online 
advertising.
People register with MindSpot by creating an account 
and completing a screening assessment, online or by 
telephone. The screening assessment includes questions 
on demographic and service use information, and symp-
toms and current stressors. Participants are also asked 
about suicidal thoughts and plans. Those who disclose 
suicidal plans or intent and who can subsequently be 
contacted by telephone are administered a structured 
risk assessment aligned with the New South Wales 
Government best practice guidelines,17 and safety plans 
are developed for all users to assist them to stay safe 
while seeking treatment or in the event of an increase in 
symptoms during treatment.18 Those unable to be con-
tacted are referred to local police for a welfare check. 
People who continue to express suicidal intent are 
referred to local mental health services or emergency 
services, depending on the urgency of the situation. 
However, patients with suicidal thoughts can also 
continue to access MindSpot services if they agree to a 
safety plan. MindSpot operates under compre hensive 
internal and external oversight and reporting that 
includes clinical, organis ational, and infor mation tech-
nology governance frameworks. The clinical governance 
frameworks align with Australian national standards for 
mental health services and include policies, systems, 
and protocols for identifying patients or others at risk, 
their management, clinical escalation in the event of 
increased risk, and training and supervision of staff.
People who do not complete an assessment are sent 
information about managing symptoms, contact details 
for crisis services, and are invited to contact MindSpot. 
People who complete the assessment are invited to 
discuss their results with a therapist by tele phone 
(appendix p 1), who provides tailored advice over the 
appointment of approxi mately 25 min. An assess ment 
report that identifies clinically significant symptoms 
and includes information about how to access mental 
health services (including those offered by MindSpot) 
or other services, is sent by the therapist to the patient 
and, if requested by the patient, to a nominated health 
pro fessional, usually a general practitioner. Information 
is also provided about evidence-based techniques for 
self-managing symp toms. Participants who complete 
an assessment and elect for a MindSpot digital treat-
ment course are then enrolled, unless they are 
considered ineligible for digital treatment by the thera-
pist because their clinical presentation suggests the 
need for compre hensive or urgent face-to-face assess-
ment. Those cases are sup ported to access specialist 
services.
MindSpot delivers seven digital treatment courses, 
which were developed and validated in a series of ran-
domised controlled trials at the Macquarie University 
online research clinic, the eCentreClinic. Four of the 
treatment courses are based on transdiagnostic principles 
recognising that people often experience symp toms of 
anxiety and depressive disorders simul taneously, and that 
similar psychological skills are used to treat these symp-
toms. The four transdiagnostic courses offered by the 
MindSpot Clinic are Mood Mechanic (for individuals 
aged 18–25 years), the Wellbeing Course (26–65 years), 
Wellbeing Plus (>65 years), and the Indigenous Wellbeing 
Course (for Aboriginal and Torres Strait Islander peo-
ple).14,19–22 These four interventions comprise evidence-
based psychological treatment components, including 
psycho education about mediators and moderators of 
symptoms, cognitive therapy, behavioural activation, 
graded exposure, sleep training, communication and 
inter personal skills, problem solving, and relapse pre-
vention.19,20 MindSpot also offers disorder-specific courses 
for obses sive compulsive disorder, post-traumatic stress 
disorder, and chronic pain. Patients can choose a treat-
ment course based on symptoms and demo graphic 
characteristics, and via telephone consul tation with a 
MindSpot therapist.
All courses consist of five lessons delivered over 
8 weeks. Each lesson comprises a series of slides that 
presents the principles of psychological treatment for the 
target symp toms via text and images, based on an 
instructional design that accommodates both didactic 
and case-based learning.20 Course completion is defined 
as completion of four or more lessons. Courses are 
delivered online with regular support initiated from the 
therapist once a week, either via telephone, secure email, 
or both. The therapist is also available at any time 
throughout the course. The approximate amount of 
therapist time per patient per course ranges from around 
1·5 h to 3 h.10 Therapist time includes all contact with 
patients, pre paration time for each patient including 
reading and responding to messages, and administration 
For the eCentreClinic see 
www.ecentreclinic.org
For the Australian Department 
of Health national standards 






See Online for appendix
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and super vision time during treatment and during 
follow-up. Course materials are available online, although 
around 10% of people elect to receive materials via a 
printed workbook, sent by postal mail. In addition to the 
therapist-delivered treatment courses, a 6 month trial of 
telephone-based counselling was conducted in 2018, and 
a self-guided version of the Wellbeing Course was intro-
duced in 2019, the results of which will be reported 
elsewhere.
Treatment outcome measures
Standardised and validated symptom questionnaires are 
administered to patients at the screening assessment and 
throughout treatment. For the purposes of this study, 
treatment out comes on the Patient Health Questionnaire-9 
(PHQ-9), Generalized Anxiety Disorder 7-Item Scale 
(GAD-7), and Kessler Psychological Distress 10-Item Plus 
Scale (K-10+) were analysed as treatment outcomes. 
The PHQ-9 consists of nine items measuring symp-
toms of major depressive disorder according to criteria of 
the Diagnostic and Statistical Manual of Mental 
Disorders, 5th edition.23 Scores range from 0 to 27, with a 
score of 10 or more indicating a diagnosis of depression. 
The GAD-7 consists of seven items and is sensitive to the 
presence of generalised anxiety disorder, social phobia, 
and panic disorder.24 Scores range from 0 to 21, with a 
score of 8 or more indicating the probable presence of an 
anxiety disorder.25 The K-10+ was used as a secondary 
outcome measure to assess general psychological distress 
and disability. The first ten items comprise the Kessler 
Psychological Distress 10-Item Scale (K-10), with scores 
ranging from 10 to 50 and scores of 21 or more associated 
with the presence of anxiety and depressive disorders.26 
The K-10+ contains four additional questions used to 
assess the functional effect of the psychological distress.27 
In the current analysis, we used two of the additional 
questions to assess the number of full and part days 
a person had been out of role (unable to do usual duties 
and activities) in the past month. We also report the 
quantifiable K-10 score. Patients are admin istered the 
PHQ-9 and GAD-7 at the screening assessment, once a 
week during treatment (days 1, 8, 15, 22, 29, 36, and 43), 
post-treatment (day 50), and at a 3 month follow-up 
(day 162). Patients complete the K-10+ at the screening 
assessment, the start of treatment (day 1), midtreatment 
(day 22), post-treatment (day 50), and the 3 month follow-
up (day 162). Patients also complete a satisfaction 
questionnaire post-treatment. The satis faction questions 
we report on are: “Would you recommend this course to 
others?” and “Was it worth your time doing this course?” 
All questionnaires are delivered online and patients have 
3 weeks to complete the post-treatment and follow-up 
questionnaires before they are considered closed.
Statistical analysis
We did descriptive analyses of demographics, service 
preferences, and baseline symptoms for the total sample 
and for each year. For categorical variables, χ² analyses 
of linear-by-linear associations were used to examine 
trends with time. ANOVA was used to examine the 
significance of changes to continuous variables with time. 
χ² values represent changes in categorical variables over 
time, and F-values from ANOVA represent significant 
differences in dependent variables, with years as the 
independent variable. Generalised estimating equation 
(GEE) models with Wald’s χ² as the test for significance 
were used to examine changes in symptom measures 
from assessment to post-treatment and the 3 month 
follow-up.28 Con sis tent with the principles of intention-to-
treat analy ses, we imputed missing data for all patients 
starting treatment, using separate GEE models that 
assumed data were missing at random, and adjusted for 
baseline symptoms and lesson completion.29 An unstruc-
tured working correlation matrix and maximum likelihood 
estimation were used, and gamma distribution with a log 
link response scale was specified to address positive 
skewness in depen dent variable distributions.
We calculated the clinical significance of change in 
PHQ-9, GAD-7, and K-10 measures using per centage 
change in symptoms from baseline30 and within-group 
Cohen’s d effect sizes, based on the esti mated marginal 
means derived from GEE modelling at the screening 
assessment, post-treatment, and the 3 month follow-up. 
Reliable recovery was calculated as the proportion of 
patients whose scores were higher than the clinical 
cutoffs of primary measures (PHQ-9 ≥10 or GAD-7 ≥8) at 
assess ment and lower than the cutoffs post-treatment, 
with evidence of reliable change. Reliable change was 
defined as a change of at least 6 points on the PHQ-9 and 
at least 5 points on the GAD-7.9,31 Reliable deter ioration in 
patients who completed treatment was defined as a score 
increase of at least 6 points on the PHQ-9 and at least 
5 points on the GAD-7 post-treatment.11 Data were 
analysed with SPSS (version 26.0). A significance level of 
0·05 was used for all tests, with the Bonferroni correction 
applied for multiple comparisons.
Role of the funding source
There was no funding source for this study.
Results
During the first 7 years of clinic operation from Jan 1, 2013, 
to Dec 31, 2019, a total of 121 652 online screening 
assessments were started, of which 96 018 (78·9%) were 
completed (figure). The number of people starting an 
assessment at MindSpot increased consistently from 
2013 to 2016, and subsequently plateaued at around 
20 000 per annum as directed by funding contracts. 
A breakdown of completed assessments by year is avail-
able in the appendix (p 2).
Demographic characteristics of the total sample and by 
year, representing all those who started the screening 
assessment, are shown in table 1. The mean age of patients 
in the total sample was 35·7 years (SD 13·8) and 
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88 702 (72·9%) were women. During the 7 years of clinic 
operation, small but significant changes were observed in 
the age, sex, Indigenous status, employment, education, 
and mar ital status of people initiating an assessment. For 
age, we observed a slight increase in the proportion of 
people aged 18–35 years with time, and less change in the 
proportion aged 55 years and older (appendix p 3). The 
proportion of women fluctuated between 71·6% and 74·3%, 
and the proportion of people married decreased from 
42·9% in 2013 to 37·0% in 2019. The proportion of patients 
born in Australia remained around 78·0%, while the 
proportion identifying as Aboriginal or Torres Strait 
Islander increased from 2·1% in 2013 to 4·4% in 2019. We 
observed some change in employment status over time, 
particularly in the proportion of students (11·1% in 2013 to 
16·0% in 2019), and a concurrent increase in the proportion 
of people with a university degree (38·3% to 40·8%). The 
proportion of patients living outside capital cities remained 
relatively stable (38·7% for the total sample of 2013–18). 
Proportions of patients from each state and territory are 
shown in the appendix (p 4). Almost a third of respondents 
were from New South Wales.
Reported psychological symptoms and stressors at the 
time of the screening assessment by year are shown in 
table 2. In 7 years of clinic operation, significant 
fluctuations were observed in symptoms. Mean scores at 
assessment (baseline) on the PHQ-9 decreased from 15·6 
(SD 6·1) in 2013 to 14·5 (6·2) in 2019, with a con current 
decrease in the proportion of people self-reporting current 
difficulties with depression during that period. Mean 
baseline scores on the GAD-7 remained close to the mean 
for the whole period (12·5 [5·2]; with the exception of 
Figure: Patient flow through the MindSpot Clinic
Course completion is defined as four or more lessons. Post-treatment completion is defined as completion of lessons and post-treatment symptom and satisfaction questionnaires. *6 month trial 
of telephone-based counselling (2018), and a self-guided version of the Wellbeing Course (introduced in 2019), the results of which will be reported elsewhere.
17 533 in Wellbeing
Course 
23 952 patients enrolled in an online therapist-guided treatment course
96 018 assessments completed
70 252 patients received an assessment report and information; no treatment enrolment
1814 patients enrolled in trials of telephone counselling or self-guided treatment*
1806 in Wellbeing 
Plus
295 in Obsessive 
Compulsive 
Disorder Course
730 in Post-traumatic 
Stress Disorder Course 
89 in Indigenous 
Wellbeing Course
2758 in Mood 
Mechanic Course 
741 in Chronic 
Pain Course































































6300/16 011 (39·3%) 
completed 3 month 
follow-up
954/1649 (57·9%) 
completed 3 month 
follow-up
104/275 (37·8%) 
completed 3 month 
follow-up 
255/657 (38·8%) 
completed 3 month 
follow-up 
19/70 (27·1%) 
completed 3 month 
follow-up
622/2405 (25·9%) 
completed 3 month 
follow-up
331/678 (48·8%) 
completed 3 month 
follow-up 
121 652 assessments started between Jan 1, 2013, and Dec 31, 2019 
25 634 assessments not completed
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Total 2013 2014 2015 2016 2017 2018 2019 Analysis of 
change over 
time
Assessments started 121 652 8929 14 729 16 917 20 672 20 461 19 660 20 284 ··
























18–34 years 66 802 (54·9%) 4587 (51·4%) 7115 (48·3%) 9476 (56·0%) 10 980 (53·1%) 11 951 (58·4%) 11 386 (57·9%) 11 307 (55·7%) ··
35–54 years 40 605 (33·4%) 3361 (37·6%) 5703 (38·7%) 5801 (34·3%) 6731 (32·6%) 6243 (30·5%) 6137 (31·2%) 6629 (32·7%) ··
≥55 years 14 245 (11·7%) 981 (11·0%) 1911 (13·0%) 1640 (9·7%) 2961 (14·3%) 2267 (11·1%) 2137 (10·9%) 2348 (11·6%) χ²=157·6, 
p<0·0001
Sex
Male 32 214 (26·5%) 2501 (28·0%) 4127 (28·0%) 4481 (26·5%) 5661 (27·4%) 5280 (25·8%) 4914 (25·0%) 5250 (25·9%) ··
Female 88 702 (72·9%) 6401 (71·7%) 10 541 (71·6%) 12 345 (73·0%) 14 892 (72·0%) 15 030 (73·5%) 14 609 (74·3%) 14 884 (73·4%) ··
Other 736 (0·6%) 27 (0·3%) 61 (0·4%) 91 (0·5%) 119 (0·6%) 151 (0·7%) 137 (0·7%) 150 (0·7%) χ²=59·6,  
p<0·0001
Locality*†






10 456/17 443 
(59·9%)
11 192/18 032 
(62·1%)
11 428/18 523 
(61·7%)
11 471/18 986 
(60·4%)
··






































13 666/17 377 
(78·6%)
13 976/17 908 
(78·0%)
14 161/18 269 
(77·5%)
14 547/18 604 
(78·2%)
··














































13 089/13 634 
(96·0%)
13 343/13 923 
(95·8%)
13 503/14 048 
(96·1%)
13 797/14 432 
(95·6%)
χ²= 98·7,  
p<0·0001
Employment*












10 535/18 562 
(56·8%)
11 350/19 015 
(59·7%)
··

























































































































11 673/18 064 
(64·6%)
12 088/18 518 
(65·3%)




*Data were missing from incomplete assessments; available data are shown in each cell. †Question introduced July, 2015. ‡Question introduced Sept, 2013. §Only patients who answered yes to being born in 
Australia were asked about Indigenous status, and not all patients provided an answer on Indigenous status.
Table 1: Demographic characteristics
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12·9 in the first year), although the pro portion reporting 
anxiety or worry increased over the 7 years. Mean baseline 
K-10 scores decreased slightly, from 32·2 (7·5) in 2013 to 
31·3 (7·6) in 2019. Based on a series of questions speci-
fically about suicidal thoughts, intentions, and plans, the 
proportion of people reporting thoughts relating to 
suicide fluctuated between 29·9% and 34·7%, while the 
proportion reporting both suicidal thoughts and current 
intent or a plan increased from 2·4% in 2013 to 3·5% in 
2019. Signi ficant changes over time were also observed in 
reported psycho social stressors. The proportion of people 
repor ting relationship difficulties increased, while the 
pro portions of people reporting vocational, physical 
health, or financial difficulties decreased (table 2).
Service use and preferences by year are reported in 
table 3. Significant changes were observed in the main 
reported purpose of using MindSpot among patients 
during the first 7 years of clinic operation. From 
2013 to 2019, the proportion of people using MindSpot 
primarily for assessment and infor mation increased from 
52·6% in 2013 to 66·7% in 2019, while the prop ortion 
primarily seeking online treatment decreased, from 
42·6% in 2013 to 26·7% in 2019. Table 3 also reports the 
reasons participants gave for using an online service 
rather than a face-to-face service. Since intro duction 
of the question in 2015, around a third of respondents 
consistently reported convenience and (absence of) cost, 
and another third reported privacy and anonymity as 
their main reason. Over 7 years, 27·7% to 37·6% patients 
reported that they had never previously seen a mental 
health professional. 45·9% to 48·7% patients reported 
speaking to a general practitioner about their mental 














31·8 (7·5) 32·2 (7·5) 32·0 (7·5) 31·9 (7·4) 31·7 (7·5) 31·9 (7·4) 31·8 (7·5) 31·3 (7·6) F=19·3, 
p<0·0001
Functional effect of symptoms (Kessler Psychological Distress 10-Item Plus Scale)*
Whole days out of 
role in past month
5·6 (7·4) ·· ·· ·· ·· 5·7 (7·5) 5·6 (7·4) 5·4 (7·4) F=3·9,  
p=0·019
Part days out of role 
in past month











10 998/15 161 
(72·5%)
12 513/17 443 
(71·7%)
12 929/17 823 
(72·5%)
13 096/18 273 
(71·7%)






























12 151/15 161 
(80·1%)
14 340/17 443 
(82·2%)
14 469/17 823 
(81·2%)
15 337/18 273 
(83·9%)












10 322/13 876 
(74·4)
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10 447/16 023 
(65·2%)
11 237/17 564 
(64·0%)




























































Data are mean (SD) or n/N (%), where numerators are the number of positive responses and denominators are the number of patients who provided an answer to that question. *Questions introduced July, 2017. 
†Questions regarding the duration of symptoms (anxiety or depression >12 months) were introduced Sept, 2013; for both, the denominator is the number of people who reported current relevant symptoms 
and provided a response to the duration question. ‡Missing data for the last quarter of 2014 due to system changes.
Table 2: Psychological symptoms at assessment
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health (accounting for no data in 2013–14 and 2018). The 
proportion of patients reporting current treatment with 
psychotropic medi cation decreased from 32·0% in 2013 
to 27·7% in 2019.
23 952 patients enrolled in treatment in a therapist-
guided online course. Due to the age range of people 
enrol ling in treatment, most (17 533 [73·2%]) elected to 
access the Wellbeing Course (table 1, figure). 
21 745 (90·8%) enrolled patients started treatment, of 
whom 14 503 (66·7%) completed treatment (ie, ≥4 lessons; 
figure). Patient satis faction was high. Among respondents 
to the post-treatment satisfaction questionnaire, 12 452 
(96·6%) of 12 895 reported that they would recommend 
the course to others and 12 433 (96·7%) of 12 860 rep orted 
that partici pating in the course was worth their time 
(appendix p 5). 
Treatment outcomes are shown in table 4. Effect sizes 
and percentage changes were large for estimated mean 
scores on the PHQ-9 and GAD-7 from assessment to 
post-treatment (PHQ-9, Cohen’s d effect size 1·40 
[95% CI 1·37–1·43]; and GAD-7, 1·45 [1·42–1·47]) and 
the 3 month follow-up (PHQ-9, 1·36 [1·34–1·38]; and 
GAD-7, 1·42 [1·40–1·44]). Similar results were observed 
for K-10 scores. These results indicated marked 
improvement in clinical symptoms. We also identified a 
small but clinically significant improvement in the 
number of whole and part days out of role. In primary 
measures, the proportions of patients with reliable 
recovery were high (5419 [59·5%] of 9105 patients with 
clinically significant symptoms at assessment on the 
PHQ-9 and 5862 [59·8%] of 9810 on the GAD-7) and the 
proportions with reliable deterioration were low 
(184 [1·4%] of 13 058 patients who completed the post-
treatment questionnaire on PHQ-9 and 282 [2·2%] of 
13 058 on the GAD-7) post-treatment.
GEE analyses showed significant overall symptom 
reductions in PHQ-9 (Wald’s χ²=29 432·8, p<0·0001), 
GAD-7 (Wald’s χ²=27 731·1, p<0·0001), and K-10 (Wald’s 
χ²=33 261·8, p<0·0001). Pairwise comparisons showed 
that scores on all measures decreased significantly from 
assessment to post-treatment and from assessment to 
follow-up (all p<0·0001). Analyses of the clinical signi-
ficance of treatment outcomes by year revealed consistent 
results, with symptom reductions post-treatment for all 
years on all measures (appendix pp 5–7).
Discussion
This study described the demographic characteristics, 
service preferences, and symptoms of more than 
120 000 users of a national DMHS, collected during 7 years 
of clinic operations. Users of the service repre sented a 
broad cross-section of the Australian popu lation, many of 
whom were seeking a confidential assessment rather than 
treatment. Those who did engage in treat ment achieved 
significant reductions in symptoms that were sustained 
for up to 3 months. The results confirm the efficacy and 
efficiency of MindSpot in provi ding evidence-based 
assessment and treatment to large numbers of people, 
Total 2013 2014 2015 2016 2017 2018 2019 Analysis of 
change over 
time
Main purpose of using MindSpot*
Assessment and 
information












13 661/19 049 
(71·7%)
12 944/19 394 
(66·7%)
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Main reason for choosing MindSpot over traditional services†
Privacy and anonymity 28 533/86 128 
(33·1%)











Convenience and cost 29 038/86 128 
(33·7%)











Other 28 557/86 128 
(33·2%)

































Never seen a health 
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Speaks to general 
practitioner about 
mental health‡
27 129/57 176 
(47·4%)










Data are n/N (%), where numerators are the number of positive responses and denominators are the number of patients who provided an answer to that question. *Missing data from July to Dec, 2017, due to 
system changes. †Data available from July, 2015. ‡Question introduced April, 2015; missing data for 2018 due to system changes.
Table 3: Mental health service preferences and use at assessment
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many of whom are not accessing other services. Our 
findings contribute to the evidence in support of DMHS 
within contemporary mental health systems.
Consistent with reports before 2018,11,12 MindSpot has 
continued to serve a broad and geographically dispersed 
cross-section of the Australian population. Some changes 
in demographics and symp toms have occurred with time, 
including an increase in the proportion of young adult 
users, an increase in the proportion identifying as 
Aboriginal or Torres Strait Islander, and an increase in 
people reporting anxiety.
A key observation was the increase in proportions of 
people reporting a primary purpose for contacting 
MindSpot was to receive an assessment rather than 
treatment. Many patients reported to therapists that a 
confidential assessment was the only intervention 
required at the time of consultation. This finding 
suggests that a dis cussion with a therapist about the 
nature of symptoms and treatment options is valued by 
many people, and can serve as a brief therapeutic 
intervention in itself. The data also raise important 
questions about engagement and attrition in digital and 
traditional mental health services, and whether all 
patients accessing a service can be assumed to be 
treatment-seeking.8 These results confirm our view that 
DMHS should align with patient-centred models of 
care, and offer a range of services, including education, 
assessment, triage, support to access urgent help for 
people in crisis, and referral, as well as providing 
evidence-based treatment.
With regard to treatment outcomes, the overall magni-
tude of clinical improvements obtained across the 
MindSpot treatment courses remain consistently high, 
with greater than 50% symptom reductions in anxiety 
and depression post-treatment, which were sustained for 
up to 3 months. Outcomes compare favourably with 
bench marks relating to substantial clinical improvement, 
low rates of deterioration, and high patient satisfaction 
with DMHS in other countries,32 including when offered 
in primary care,33 and via other initiatives for large-scale 
implementation of psychological treatment in Australia34 
and the UK.9
This study has several limitations. We report on 
characteristics and outcomes of patients registering for 
assessment or treatment with MindSpot, which res-
tricted our sample to a small proportion of visitors to the 
MindSpot website (>500 000 per year), and limits the 
generalisability of our results. We also acknowledge the 
issue of missing responses, which is a limitation of 
many studies, particularly those reporting outcomes 
obtained in routine care, in which patients are receiving 
a service rather than participating under controlled trial 
con ditions. The absence of a control group also means 
that we are unable to account for natural remission or 
the effect of missing data. However, this limitation was 
mitigated by the weekly collection of symptom scores 
during treatment and by conservative statistical mod-
elling,30 and we found no indication of systematic bias in 
trends over time due to missing data. A post-hoc analysis 
did find some evidence that young patients and those 
Estimated mean* Cohen’s d effect size from 
assessment
Percentage change in 






























































Functional effect (Kessler Psychological Distress 10-Item Plus Scale; n=5120)
Whole days out of 
role


















Data are mean (SD), % change (95% CI), effect size (95% CI), or n/N (%); for reliable recovery, numerators are number of patients meeting thresholds for reliable recovery and 
denominators are number of patients with clinically significant symptoms at assessment and complete post-treatment questionnaires, and for reliable deterioration, 
numerators are number of patients meeting threshold for reliable deterioration and denominators are number of patients who completed the post-treatment 
questionnaires. *Estimated marginal means derived from generalised estimating equation modelling. †Reliable deterioration and reliable recovery calculated from actual 
scores post-treatment. ‡After transformation to 0–40 scale for calculation of percentage change from scores of 10–50.
Table 4: Treatment outcomes
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with severe symptoms are not necessarily continuing to 
or completing treatment (appendix p 8), which might 
affect the generalisability of our results.
Generally, we found that several key demographic 
factors, such as the proportion of people born overseas, 
distribution by states and territories, Indigenous status 
(Aboriginal and Torres Strait Islander), and proportion 
living in rural or remote regions, closely matched 
national statistics.12 However, we acknowledge that other 
factors might be under-represented or over-represented 
in our sample. For example, the proportion of men con-
tacting MindSpot was always less than 30%, an under-
representation consistent with reports that men are less 
likely to seek help for anxiety and depression from 
traditional mental health services, despite having higher 
rates of suicide than women.35,36 The question of how to 
engage men in both traditional mental health services 
and DMHS remains important and might require new 
service models.
Despite these limitations, our results show that a 
high-volume digital mental health service can be success-
fully implemented as part of routine care. The main 
stren gths of this study are the analyses of comprehensive 
data on a large consecutive sample, combined with the 
regular measurement of symptoms to monitor treatment 
effects. Furthermore, treatment results over 7 years match 
those reported in earlier papers, confirming the robust 
nature of the digitised clinic procedures and clinical 
effects.
As of 2020, MindSpot has been operating for more 
than 7 years. In that time, the delivery of health care, 
including some forms of mental health care, via digital 
technology has become increasingly acceptable. Services 
such as MindSpot have shown that digital deli very of care 
increases accessibility and convenience for patients and 
can reduce other barriers to care such as stigma. Other 
key learnings from MindSpot are that DMHS could have 
an important role in contem porary mental health care, 
not only by providing treat ment, but also by providing 
infor mation and assessment services to diverse groups of 
people that often under-utilise traditional health services, 
including Indigenous Australians, and people living in 
rural and remote regions.8,14 We maintain that DMHS are 
not a panacea and should not replace existing services, 
but instead can complement those services by reducing 
barriers and delivering evidence-based care to large num-
bers of patients in an efficient and cost-effective way.8,37 
People who do not respond to DMHS can then be 
supported to seek more intensive treatment, consistent 
with a stepped-care approach.9
An important feature of DMHS is the potential for 
systematic measurement of progress via treatment and 
outcomes, which is rarely implemented with existing 
service models.9 By providing services to large numbers 
of people and routinely collecting and reporting data 
about user characteristics and clinical outcomes, 
DMHS are not only providing valuable benchmarking 
data, but are having a growing influence on the 
planning of mental health systems across an increasing 
number of countries. The routine collection and 
reporting of user data, with the exception of the UK’s 
IAPT model, is not typical of publicly funded psycho-
logical services. Thus, such reporting by DMHS is not 
only increasing unde rstanding among policy makers 
on the relative strengths and limitations of different 
service models, but is likely to lead to increased expec-
tations from funders and policy makers for similar 
reporting from traditional services. In the long term, 
this influence might lead to policy and funding 
decisions based more on evidence than traditional prac-
tice, but in the short term this will require change in 
the culture and operations of services that do not 
routinely collect or report these kind of data.
Developing, delivering, and evaluating DMHS is 
challenging, requiring complex procedures and on-
going evaluation in the context of ever-changing 
technology and a rapidly evolving governance and 
regulatory envi ronment. Despite the challenges, we no 
longer need to question whether DMHS will become 
part of the frame work of mental health services. The 
new question is, how will this integration occur and 
how do we best integrate DMHS with existing face-to-
face services? Based on the preferences of many 
patients for more easily accessible, confidential mental 
health care, we believe that a need will be ongoing for 
stand-alone services, which provide the option of 
assessment and treatment and are not always linked 
with an existing provider. Ideally, existing mental health 
services should receive support to deliver both face-to-
face and digital mental health care, and we strongly 
recommend engagement during the development and 
implementation of these services with patients and 
other stakeholders, including policy makers and 
funders, to ensure that services are not only effective 
but also acceptable. Mental health professionals could 
then be trained and equipped to use digital tools with 
their own clients, to improve both quality of care and 
collection of treatment outcome data. Without such 
training and support, patients are unlikely to receive 
consistently high-quality care, and funders are unlikely 
to receive data on clinical outcomes to guide service or 
programme improvements.
The MindSpot project has become one of the leading 
providers globally of DMHS as part of routine care and 
has deli vered mental health services with proven 
effectiveness to a large number of Australians in its 
first 7 years. The consistency of results provides support 
for the adoption of this model of care within the 
national mental health system, particularly in the 
present context of increased consumer acceptance of 
digital and telephone health-care services. Nonetheless, 
we maintain that the role of DMHS is to provide 
consumers and referrers with an additional choice of 
service model.
For the Australian National 
Mental Health Service 
Planning Framework see 
http://nmhspf.org.au/
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